AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35134259
Drug: Avatrombopag 40
RxNorm normalized name: avatrombopag 40 MG Daily Dose, 20 MG Oral Tablet 10 Count Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag 40 mg
Trial: 35134259
Drug: Avatrombopag 60
RxNorm normalized name: avatrombopag 60 MG Daily Dose, 20 MG Oral Tablet 15 Count Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatrombopag 60 mg
Trial: 35134880
Drug: Ibezapolstat 450
RxNorm normalized name: Ibezapolstat
DrugBank: Ibezapolstat (DB16189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibezapolstat 450 mg orally every 12 hours for 10 days
Trial: 35135499
Drug: Booklet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booklet-based intervention for diabetic hypoglycaemia (Hypos can strike twice)
Trial: 35135700
Drug: MMR vaccination
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccination (two doses)
Trial: 35135832
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccine (CoronaVac)
Trial: 35135832
Drug: Prednisone >7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone >7.5 mg/day
Trial: 35136603
Drug: Autologous chimeric
RxNorm normalized name: Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous chimeric antigen receptor (CAR) αβ T-cell therapies
Trial: 35137142
Drug: Suppressed adrenocorticotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppressed adrenocorticotropic hormone (≤2.2 pmol/L)
Trial: 35137228
Drug: ONC201 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ONC201 treatment
Trial: 35137627
Drug: Low-dose sublingual
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sublingual fentanyl
Trial: 35137871
Drug: ELMOcpap system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELMOcpap system (CPAP via ELMO interface with oxygen and compressed air flow meters at 30 L/min each, PEEP valve, CPAP levels = 8-10 cmH2O)
Trial: 35137871
Drug: ELMOcpap system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELMOcpap system (CPAP at 10 cmH2O, total gas flow of 56-60 L/min)
Trial: 35138325
Drug: Sequential algorithm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential algorithm using 3-D LVEF, GLS, and GCS
Trial: 35138442
Drug: Appropriate DOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate DOAC dosage
Trial: 35138442
Drug: Inappropriate DOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate DOAC dosage
Trial: 35138442
Drug: Survival comparison
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survival comparison between underdosage and appropriate dosage
Trial: 35138529
Drug: Afatinib plus
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib plus vinorelbine 25 mg/m
Trial: 35138529
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (afatinib plus vinorelbine or paclitaxel)
Trial: 35138919
Drug: Taselisib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taselisib monotherapy
Trial: 35139911
Drug: Systematic electronic
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic electronic screening for substance use and mental health symptoms via secure messaging and clinic-based tablets, integrated into the electronic health record (EHR).
Trial: 35139911
Drug: Multiple methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple methods of questionnaire completion (secure messaging and clinic-based tablets).
Trial: 35140147
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PHI and MRI findings
Trial: 35141162
Drug: GAD-M regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-M regimen (Gemcitabine, Peg-Asparaginase, Dexamethasone, Methotrexate) administered for 6 cycles
Trial: 35144847
Drug: MenACYW-TT conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MenACYW-TT conjugate vaccine co-administered with routine pediatric vaccines (DTaP-IPV/Hib, PCV7/PCV13, MMR, and varicella)
Trial: 35144847
Drug: MenACYW-TT conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MenACYW-TT conjugate vaccine
Trial: 35144847
Drug: Routine pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine pediatric vaccines
Trial: 35144953
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of daily iTBS treatment of left DLPFC
Trial: 35144989
Drug: Add-on inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on inhaled budesonide
Trial: 35145218
Drug: Sipuleucel-T (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sipuleucel-T (3 infusions)
Trial: 35146939
Drug: Infusional gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional gemcitabine (100 mg/m) with concurrent radiotherapy (50.4-54 Gy over 28 days)
Trial: 35148720
Drug: Standard provider-initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard provider-initiated testing using rapid antibody tests
Trial: 35149207
Drug: Arterial stiffness
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arterial stiffness (pulse wave velocity measures: carotid-femoral, femoral-foot, carotid-radial, augmentation index, brachial distensibility)
Trial: 35149591
Drug: VCN-01 administered
RxNorm normalized name: VCN-01
DrugBank: VCN-01 (DB18193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCN-01 administered intratumorally at doses up to 1×10,
Trial: 35149591
Drug: VCN-01 combined
RxNorm normalized name: VCN-01
DrugBank: VCN-01 (DB18193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCN-01 combined with standard chemotherapy,
Trial: 35149641
Drug: Ledipasvir-sofosbuvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir-sofosbuvir (90 mg/400 mg) once daily for 12 weeks
Trial: 35150293
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine (LDD) stress test at 10 µg/kg/min
Trial: 35150293
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine (LDD) stress test at 5, 10, 15 µg/kg/min
Trial: 35150293
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine (LDD) stress test
Trial: 35150296
Drug: 90-yttrium-ibritumomab tiuxetan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment
Trial: 35150356
Drug: M3541 (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M3541 (50-300 mg administered on RT fraction days)
Trial: 35150355
Drug: Sequential postural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential postural recruitment maneuver
Trial: 35151024
Drug: Healthcare provider
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthcare provider education and prescription drug monitoring programs
Trial: 35151262
Drug: 2-axis turntable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-axis turntable based BPPV treatment
Trial: 35151262
Drug: Regular testing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular testing for BPPV and treatment with appropriate liberation maneuvers
Trial: 35151268
Drug: Diosmectite (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmectite (3 g/sachet, 3 sachets/day)
Trial: 35151584
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg IV infusion every 3 weeks) plus Tazemetostat (800 mg orally BID on days 1 to 21)
Trial: 35152295
Drug: CMV viremia
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV viremia ≥ 1000 IU/mL in HEU children
Trial: 35153091
Drug: Plant-derived PA83-FhCMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-derived PA83-FhCMB vaccine at doses of 12.5, 25, 50, or 100 µg with Alhydrogel®
Trial: 35153091
Drug: Plant-derived PA83-FhCMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-derived PA83-FhCMB vaccine
Trial: 35154390
Drug: Pharyngeal electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharyngeal electrical stimulation (PES) for 10 minutes, 3 consecutive days in addition to Standard Logopaedic Therapy (SLT)
Trial: 35154390
Drug: Standard Logopaedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Logopaedic Therapy (SLT) alone
Trial: 35154704
Drug: Standard systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systemic treatment for mCRC
Trial: 35154830
Drug: MRI-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-based treatment plans
Trial: 35154830
Drug: CT-based treatment
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-based treatment plans
Trial: 35155599
Drug: Loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretic treatment
Trial: 35155859
Drug: IONIS-FXI, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS-FXI, 300 mg open-label dose
Trial: 35155863
Drug: HCV D-RNA-positive/R-negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV D-RNA-positive/R-negative kidney transplantation (KT) followed by 8 weeks of glecaprevir/pibrentasvir (G/P) initiated 2 to 5 days post-KT
Trial: 35156036
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg daily (arm A)
Trial: 35156036
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg daily (arm B)
Trial: 35156036
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg daily (arm C)
Trial: 35156036
Drug: Osimertinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib dose escalation to 160 mg
Trial: 35156068
Drug: GX-19 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-19 (1.5 mg)
Trial: 35156068
Drug: GX-19 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-19 (3.0 mg)
Trial: 35156068
Drug: GX-19N (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-19N (3.0 mg)
Trial: 35156195
Drug: Repeat dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dosing of liso-cel
Trial: 35156500
Drug: Coach-guided videoconferencing
RxNorm normalized name: coachwhip stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coach-guided videoconferencing acceptance and commitment therapy (ACT) with psychoeducation
Trial: 35156519
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy with autophagy inhibition
Trial: 35156519
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard targeted therapy without autophagy inhibition
Trial: 35156709
Drug: Anti-spike antibody
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-spike antibody titres
Trial: 35157769
Drug: Recombinant zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant zoster vaccine (RZV) in treatment naïve (TN) CLL patients
Trial: 35157769
Drug: Recombinant zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant zoster vaccine (RZV) in patients receiving BTKi therapy
Trial: 35157978
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg every 28 days) with Cetuximab and Radiotherapy
Trial: 35157988
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) models using random survival forest (RSF) method
Trial: 35158476
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets 3.5 mg/kg over 2 years
Trial: 35159082
Drug: Androgen-deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-deprivation therapy (ADT) + Docetaxel
Trial: 35159082
Drug: Androgen-deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-deprivation therapy (ADT) - Docetaxel
Trial: 35162827
Drug: ReStoreD intervention
RxNorm normalized name: Restone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReStoreD intervention (8-week remotely administered dyadic intervention)
Trial: 35164584
Drug: Surrogates' belief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surrogates' belief in the necessity of all medications
Trial: 35164584
Drug: Patients' perception
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' perception of medication burden
Trial: 35164745
Drug: Statins, ACE-I,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins, ACE-I, ARBs, diabetes medications
Trial: 35164745
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of treatment
Trial: 35164860
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plasma Aβ and gut microbiota
Trial: 35164933
Drug: No Proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Proton Pump Inhibitors (Control)
Trial: 35165103
Drug: Health-related quality
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health-related quality of life (HRQoL) assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) at baseline and at the end of the first cycle of chemotherapy.
Trial: 35165236
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (knowledge translation intervention)
Trial: 35165421
Drug: Updated mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Trial: 35166929
Drug: Surufatinib 250
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250 mg QD plus toripalimab 240 mg Q3W
Trial: 35167031
Drug: Intravenous posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous posaconazole 300 mg twice on day 1, then 300 mg once daily on days 2-10, and either 300 mg once daily or oral suspension 200 mg 3 times daily for up to 18 days for a maximum of 28 days.
Trial: 35167031
Drug: Intravenous posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous posaconazole (intensive PK group)
Trial: 35167031
Drug: Intravenous posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous posaconazole (sparse PK group)
Trial: 35167051
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg/day) as an add-on to metformin for 18 months
Trial: 38423992
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 mg twice daily
Trial: 35167187
Drug: Prednisone on
RxNorm normalized name: Prednisone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone on a tapering schedule
Trial: 35167329
Drug: Adagrasib 600
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adagrasib 600 mg twice a day
Trial: 35167586
Drug: PWUD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PWUD with TB disease who smoke illicit drugs
Trial: 35167972
Drug: Drug-free remission
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-free remission at 5 years
Trial: 35168547
Drug: Rituximab 1000
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 1000 mg on days -14 and -7, followed by gemcitabine/cisplatin every 3 weeks, and rituximab every 6 months thereafter (Protocol 1)
Trial: 35168547
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 concomitantly with gemcitabine/cisplatin (Protocol 2)
Trial: 35168605
Drug: Asprosin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asprosin treatment in HUVECs
Trial: 35169140
Drug: Treated with
RxNorm normalized name: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DrugBank: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine (DB19219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated with prednisone and/or antibiotics in the outpatient setting
Trial: 37164959
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of NDV-HXP-S vaccine
Trial: 37164959
Drug: Intranasal followed
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal followed by intramuscular administration of NDV-HXP-S vaccine
Trial: 35171350
Drug: Cabozantinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib and panitumumab combination therapy
Trial: 35171658
Drug: Sapanisertib 30
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapanisertib 30 mg by mouth once weekly
Trial: 35171913
Drug: P2Y12 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitors (duration: 12 months)
Trial: 35171913
Drug: Permanent discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent discontinuation of P2Y12 inhibitors
Trial: 35172719
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise as a treatment for chronic low back pain
Trial: 35172719
Drug: Biomedical model
RxNorm normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomedical model of treatment
Trial: 35174078
Drug: Primary tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary tumor resection (PTR) after induction chemotherapy with XELOX or mFOLFOX6
Trial: 35174078
Drug: Chemotherapy-alone (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-alone (no PTR)
Trial: 35174749
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) techniques for identifying clinical phenotypes of T2D
Trial: 35175229
Drug: Semaglutide injection
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide injection at 2.4 mg once weekly
Trial: 35175381
Drug: Unimodal ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unimodal ultrasound ML algorithms
Trial: 35175381
Drug: Multi-modal ultrasound
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal ultrasound ML algorithms
Trial: 35176457
Drug: Pemigatinib 1-20
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib 1-20 mg once daily intermittently (2 weeks on/1 week off; n = 70) or continuously (n = 58)
Trial: 35177038
Drug: Asthma control
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asthma control and oral corticosteroid use patterns
Trial: 35177299
Drug: J&J vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J&J vaccine